CR

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
CR, DLBCL, FDA, Research, CRR, Food, PTCL, G&A, B-cell lymphoma, R, Post-transplant lymphoproliferative disorder, SDD, Dor, PTLD, ORR, Safety, Therapy, Investment, Patient, Food and Drug Administration, SAN, Pharmaceutical industry, Fine chemical, Computer data storage, Nursing, Medical device

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the third quarter of 2023.

Key Points: 
  • SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today provided a business update and reported financial results for the third quarter of 2023.
  • Completion of enrollment into the nanatinostat monotherapy arm (n=10) and Nana-val combination arm (n=10) of the NAVAL-1 R/R EBV+ PTCL cohort is anticipated by year-end 2023.
  • U.S. Food and Drug Administration (FDA) meeting to discuss additional requirements for accelerated approval for the treatment of patients with R/R EBV+ PTCL.
  • On October 4, 2023, Viracta hosted an R&D Day highlighting Nana-val clinical programs in EBV-associated cancers.

TEAMSTERS RATIFY CONTRACT AT CR&R ENVIRONMENTAL SERVICES IN COLTON

Retrieved on: 
Tuesday, November 7, 2023
CR, International Brotherhood of Teamsters, Republic Services, Local, Sanitation, Multimedia, Pension fund

COLTON, Calif., Nov. 7, 2023 /PRNewswire/ -- Teamsters Local 396 members employed at CR&R Environmental Services in Colton, Calif., ratified a new contract that includes significant wage and pension increases, as well as improved health care benefits.

Key Points: 
  • COLTON, Calif., Nov. 7, 2023 /PRNewswire/ -- Teamsters Local 396 members employed at CR&R Environmental Services in Colton, Calif., ratified a new contract that includes significant wage and pension increases, as well as improved health care benefits.
  • I am proud of this agreement, which continues our legacy of delivering strong contracts for Teamsters in Southern California," said Alex Moran, Sanitation Director and President of Teamsters Local 396.
  • Members of Local 396 working at CR&R in Colton were supported by fellow Teamsters working at Republic Services, who stood shoulder-to-shoulder in solidarity with them throughout the entire bargaining process.
  • It is the largest Teamsters sanitation local in the U.S. Our sanitation members serve communities throughout Los Angeles, Orange, Riverside, and San Bernardino Counties.

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Retrieved on: 
Friday, November 3, 2023
CR, Neoplasm, Survival, WT1, MTD, DOI, H. Lee Moffitt Cancer Center & Research Institute, OH, Stomach, PDT, Ovarian cancer, EDT, Pembrolizumab, Nucleic acid thermodynamics, Infrared spectroscopy correlation table, DCR, MOS, HPV, Docetaxel, Chair, HNSCC, CPS, Phase, SITC, Cetuximab, Immunotherapy, SD, Clinical trial, Immune system, University Hospitals Cleveland Medical Center, Cancer, ORR, Blood, Methotrexate, EW, Society for Immunotherapy of Cancer, DSD, Safety, Society, Checkmate, Patient, DNA, UPR, Pharmaceutical industry, Vaccine, Communications satellite, Head, Lancet

New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.

Key Points: 
  • New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.
  • I look forward to evaluating the trial results as they continue to mature and remain highly encouraged by the observations to date.
  • Two patients at the 2mg/kg dose, one with gastric cancer and one with ovarian cancer have demonstrated reduction in tumor burden.
  • Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Trae tha Truth, ECOG, Vomiting, CYP3A4, WT, Abstract, NPM1, KMT2A, OBD, PK, DLT, TKD, Cancer, Diabetes, ORR, Clinical study design, Safety, Patient, Cohort, HSCT, SETBP1, CR, DSM-IV codes, NUP214, DOR, Dicarboxylic acid, CRi, ASH, CD135, QT interval, RFS, FLT3, Arm, Cellular, FMS, Transplant, ALL, Toxic leukoencephalopathy, Gene family, Survival, Postcholecystectomy syndrome, DS, Trial of the century, Incidence, CRC, Infrared spectroscopy correlation table, AL, Osteopathic medicine in Canada, MN1, BID, CNS, KRAS, ATD, NUP98, Society, WBC, Pharmacokinetics, CLL, Acute leukemia, Common, ITD, Toxicity, AML, Cardiovascular disease, Pharmaceutical industry, Dentistry, Vaccine, Decitabine, DLBCL

Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.

Key Points: 
  • Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.
  • Methods: Doses of BMF-219 are escalated independently for each indication, initially in single-subject cohorts followed by a “3 + 3” design.
  • A subsequent amendment introduced quotas for KMT2Ar (MLL1r), NPM1 and other known menin-dependent mutations: CEBP/A, MLL1-PTD, MN1, NUP98, NUP214, PICALM-AF10, SETBP1.
  • The study was initiated in July 2023 and will enroll ~110 participants at approximately 30 sites.

EXPANDING POSSIBILITIES: CANON ANNOUNCES FIRMWARE UPDATES FOR CINEMA EOS, CAMCORDER AND PTZ CAMERAS, GRANTING CANON CUSTOMERS BROADER OPTIONS AND MORE CONTROL

Retrieved on: 
Thursday, November 2, 2023
EOS, CR, United States Patent and Trademark Office, XF, RF, RCCA, PTZ, Canon Cinema EOS, SRT, Wi-Fi, IPhone, Shutter, Canon Inc., Canon EOS C300 Mark II, Zoom, Lens, Color balance, Iris, R5, ISO, Patent, Camera, Typesetting, Citrus, Telescopic sight, Consumer electronics, Television, Video game, Canon

Additionally, Canon announced the new Canon Multi-Camera Control App (the “app”)1.

Key Points: 
  • Additionally, Canon announced the new Canon Multi-Camera Control App (the “app”)1.
  • All firmware updates and the app will be available to customers for free download in early December 2023*.
  • Highlights for each of the Canon Cinema EOS products:
    Supports camera control from the new RC-IP1000 Remote Camera Controller.
  • Enhancements to the vector scope will now enable display of the vector color and color-space on screen.

Kura Oncology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
CR, Research, Mirati Therapeutics, NSCLC, AACR, Kura, Acute myeloid leukemia, FTI, Hematology, Mirati, Conference, KMT2A, CRH, KRAS, Azacitidine, HRAS, HNSCC, Disease, ID, Marketing, Webcast, Cancer, KURA, Oncology, Venetoclax, Mixed-phenotype acute leukemia, FLT3, Safety, European Society of Gynaecological Oncology, Renal cell carcinoma, Investment, Patient, Therapy, AML, Pharmaceutical industry, Bank, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2023 were $29.3 million, compared to $25.0 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $13.1 million, compared to $11.6 million for the third quarter of 2022.
  • ET / 1:30 p.m. PT today, November 2, 2023, to discuss the financial results for the third quarter 2023 and to provide a corporate update.

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Retrieved on: 
Thursday, November 2, 2023
B-cell lymphoma, Rheumatoid arthritis, Mantle cell lymphoma, Symantec Endpoint Protection, Ulcerative colitis, Pulmonary embolism, Lupus, CET, Infection, SLE, RT, Bleeding, ORR, Safety, Patient, TYK2, Baltic, DLBCL, CR, Euronext, Galapagos NV, Failure mode and effects analysis, ASH, UK, Follicular lymphoma, Letter, CRS, Non-Hodgkin lymphoma, Survival, ET, Technology transfer, CRR, UC, CD19, Indolent lymphoma, CFO, Burn, Lymphoid leukemia, Pharmaceutical industry, Cryptocurrency, Vaccine, Uranium mining, Pamlab, Galápagos Islands, Dermatomyositis, Central Europe

Overall, 11 of 12 patients responded to treatment (ORR of 92%) and 9 of 12 patients achieved a CRR (75%).

Key Points: 
  • Overall, 11 of 12 patients responded to treatment (ORR of 92%) and 9 of 12 patients achieved a CRR (75%).
  • Overall, 11 of 13 patients responded to treatment (ORR of 85%) and 9 of 13 patients achieved a CRR (69%).
  • New preliminary data (data cut-off: 26 April 2023), for 12 patients enrolled in EUPLAGIA-1, will be presented at ASH (see ASH abstract and poster presentation details below).
  • New preliminary data (data cut-off: 2 May 2023) for 14 patients enrolled in ATALANTA-1 will be presented at ASH (see ASH abstract and poster presentation details below).

ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CR, Rat, Neoplasm, Patient, Pneumonitis, Ovarian cancer, PDT, Trae tha Truth, MPH, Therapy, Endometrial cancer, Pharmacokinetics, Safety, Conjugation, PTK7, MMAE, SITC, Immunotherapy, SD, Bone marrow, ADC, Spacecraft, Breast cancer, Mesothelioma, Lung cancer, Society, Cancer, Cytopenia, Therapeutic index, Fatigue, Fine chemical, Medical imaging, Vaccine, Pharmaceutical industry, Communications satellite, Part

ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).

Key Points: 
  • ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).
  • “We are thrilled to present proof-of-concept data from our novel sesutecan ADC platform with the initial clinical results for Rina-S,” said ProfoundBio Chief Medical Officer Naomi Hunder, M.D.
  • Enrolled patients had the following tumor types: ovarian cancer (n=17), endometrial cancer (n=9), breast cancer (n=3), non-small cell lung cancer (n=5), and mesothelioma (n=2).
  • Superior tumor growth inhibition and tolerability relative to the precedent PTK7-directed ADC cofetuzumab pelidotin were observed in head-to-head preclinical studies.

Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CR, Society for Hematology and Stem Cells, Acute lymphoblastic leukemia, Acute myeloid leukemia, Bone marrow, PTCL, CD123, PFS, Cohort, Skin, CRS, Complete Response Letter, Poster, IPH, Society, Notifiable disease, ASH, Euronext Paris, Abstract, Blood, ORR, CBR, IPHA, Safety, Exposition, DLS, AML, Pharmaceutical industry, Patient, Sanofi

Clinical Benefit Rate (CBR, defined as CR+PR+SD) was 87.5 % (n=49; 95% CI 76.4-93.8).

Key Points: 
  • Clinical Benefit Rate (CBR, defined as CR+PR+SD) was 87.5 % (n=49; 95% CI 76.4-93.8).
  • Continued evaluation of this promising new targeted treatment option for patients with Sezary Syndrome is warranted.
  • The poster will display preclinical combination data supporting anti-tumor activity and rationale for the exploration of lacutamab in combination with approved and novel therapies in patients with PTCL.
  • SAR443579 was well tolerated up to doses of 6000 μg/kg QW with observed clinical benefit in patients with R/R AML.

Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CR, Renal cell carcinoma, Nivolumab, Society for Immunotherapy of Cancer, HPK1, MBA, Protein, Poster, Pharmacokinetics, SITC, Immunotherapy, B cell, Clinical trial, Annual general meeting, Pancreatic cancer, MAP4K, Safety, Society, Cancer, Therapy, Patient, Combination therapy, Pharmaceutical industry, Nimbus

The data presented at SITC include initial safety and efficacy results from single agent therapy (n=13) in the dose escalation portion of the trial.

Key Points: 
  • The data presented at SITC include initial safety and efficacy results from single agent therapy (n=13) in the dose escalation portion of the trial.
  • “We’re pleased to share these first clinical data from our clinical trial of NDI-101150.
  • In a second poster at SITC, Nimbus is presenting new preclinical data which support the potential for both broad immunotherapeutic potential and best-in-class selectivity of NDI-101150 among publicly disclosed HPK1 inhibitor programs to date.
  • “The data presented at SITC reinforce the potential first-in-class and best-in-class profile of our HPK1 inhibitor, and we will continue to work to realize its possible benefits to patients with cancer.”